25 January 2021

Patients in England with mantle cell lymphoma that has returned or won’t respond to treatment can now benefit from a new cell-based therapy, backed by the National Institute for Health and Care Excellence (NICE).

The treatment, called Tecartus, or autologous anti-CD19-transduced CD3+, is a form of chimeric antigen receptor-T cell (CAR-T) therapy.

The treatment will be available from ten NHS providers immediately after guidance was released last week. These are hospitals that currently have sufficient critical care capacity required to administer CAR-T cell treatments.

To be eligible for Tecartus, people with mantle cell lymphoma must have previously received treatment with a Bruton’s tyrosine kinase inhibitor, such as ibrutinib.

The agreement to make the new drug immediately available has been made between the NHS, NICE and pharmaceutical manufacturer Kite Pharma, owned by Gilead Sciences, through the UK Cancer Drugs Fund scheme. This allows patients to access the treatment while NICE collects additional data to help it decide whether it should be routinely funded.

So far, the research evidence suggests that Tecartus may improve survival and ensure a longer duration before relapse. But trials are yet to show whether the therapy can be considered a full cure, NICE said.

It is anticipated that about 100 patients a year might receive Tecartus, and they will be followed to collect information on progression-free survival and overall survival.

Meindert Boysen of NICE said: “We are pleased to be able to recommend another revolutionary CAR T-cell therapy, this time for adults with mantle cell lymphoma, which represents a step forward for personalised medicine.

“The treatment is specific to each individual and could be a potential cure for some, although it is early days. Our recommendation for Tecartus, on the Cancer Drugs Fund, means people can benefit while more data is collected.”

Source: NICE

Link: https://www.nice.org.uk/guidance/indevelopment/gid-ta10312


Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.

News service provided by Englemed News http://www.englemed.co.uk/